FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109106979> ?p ?o ?g. }

• W3109106979 endingPage "205031212097350" @default.
• W3109106979 startingPage "205031212097350" @default.
• W3109106979 abstract "Although angiotensin II receptor blockers are effective for patients with chronic kidney disease, dose-dependent renoprotective effects of angiotensin II receptor blockers in patients with moderate to severe chronic kidney disease with non-nephrotic proteinuria are not known. Our aim was to elucidate the dose-dependent renoprotective effects of angiotensin II receptor blockers on such patients.A multicenter, prospective, randomized trial was conducted from 2009 to 2014. Patients with non-nephrotic stage 3-4 chronic kidney disease were randomized for treatment with either 40 or 80 mg telmisartan and were observed for up to 104 weeks. Overall, 32 and 29 patients were allocated to the 40 and 80 mg telmisartan groups, respectively. The composite primary outcome was renal death, doubling of serum creatinine level, transition to stage 5 chronic kidney disease, and death from any cause. Secondary outcomes included the level of urinary proteins and changes in the estimated glomerular filtration rate.There was no difference in the primary outcome (p = 0.78) and eGFR (p = 0.53) between the two groups; however, after 24 weeks, urinary protein level was significantly lower in the 80 mg group than in the 40 mg group (p < 0.05). No severe adverse events occurred in either group, and the occurrence of adverse events did not significantly differ between them (p = 0.56).Our findings do not demonstrate a direct dose-dependent renoprotective effect of telmisartan. The higher telmisartan dose resulted in a decrease in the amount of urinary protein. Even though high-dose angiotensin II receptor blockers may be preferable for patients with stage 3-4 chronic kidney disease, the clinical importance of the study results may be limited. The study was registered in the UMIN-CTR (https://www.umin.ac.jp/ctr) with the registration number UMIN000040875." @default.
• W3109106979 created "2020-12-07" @default.
• W3109106979 creator A5011627081 @default.
• W3109106979 creator A5025133766 @default.
• W3109106979 creator A5025661789 @default.
• W3109106979 creator A5025902898 @default.
• W3109106979 creator A5036382221 @default.
• W3109106979 creator A5037349090 @default.
• W3109106979 creator A5071159100 @default.
• W3109106979 creator A5071671184 @default.
• W3109106979 creator A5086116258 @default.
• W3109106979 date "2020-01-01" @default.
• W3109106979 modified "2023-09-28" @default.
• W3109106979 title "Renal outcomes of treatment with telmisartan in patients with stage 3–4 chronic kidney disease: A prospective, randomized, controlled trial (JINNAGA)" @default.
• W3109106979 cites W1987512785 @default.
• W3109106979 cites W1990609671 @default.
• W3109106979 cites W1994334230 @default.
• W3109106979 cites W1994577047 @default.
• W3109106979 cites W1996528098 @default.
• W3109106979 cites W2003895389 @default.
• W3109106979 cites W2021232559 @default.
• W3109106979 cites W2021988356 @default.
• W3109106979 cites W2043066499 @default.
• W3109106979 cites W2048414885 @default.
• W3109106979 cites W2049276892 @default.
• W3109106979 cites W2052653818 @default.
• W3109106979 cites W2059911502 @default.
• W3109106979 cites W2063210769 @default.
• W3109106979 cites W2065876809 @default.
• W3109106979 cites W2067853547 @default.
• W3109106979 cites W2082494967 @default.
• W3109106979 cites W2087285082 @default.
• W3109106979 cites W2093754226 @default.
• W3109106979 cites W2097337104 @default.
• W3109106979 cites W2120235169 @default.
• W3109106979 cites W2131460202 @default.
• W3109106979 cites W2145555664 @default.
• W3109106979 cites W2157382533 @default.
• W3109106979 cites W2160547085 @default.
• W3109106979 cites W2218839371 @default.
• W3109106979 cites W2314168905 @default.
• W3109106979 cites W2475261460 @default.
• W3109106979 cites W2476959638 @default.
• W3109106979 cites W2744929116 @default.
• W3109106979 cites W3040786045 @default.
• W3109106979 cites W4211170672 @default.
• W3109106979 doi "https://doi.org/10.1177/2050312120973502" @default.
• W3109106979 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7686635" @default.
• W3109106979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33282300" @default.
• W3109106979 hasPublicationYear "2020" @default.
• W3109106979 type Work @default.
• W3109106979 sameAs 3109106979 @default.
• W3109106979 citedByCount "1" @default.
• W3109106979 countsByYear W31091069792023 @default.
• W3109106979 crossrefType "journal-article" @default.
• W3109106979 hasAuthorship W3109106979A5011627081 @default.
• W3109106979 hasAuthorship W3109106979A5025133766 @default.
• W3109106979 hasAuthorship W3109106979A5025661789 @default.
• W3109106979 hasAuthorship W3109106979A5025902898 @default.
• W3109106979 hasAuthorship W3109106979A5036382221 @default.
• W3109106979 hasAuthorship W3109106979A5037349090 @default.
• W3109106979 hasAuthorship W3109106979A5071159100 @default.
• W3109106979 hasAuthorship W3109106979A5071671184 @default.
• W3109106979 hasAuthorship W3109106979A5086116258 @default.
• W3109106979 hasBestOaLocation W31091069791 @default.
• W3109106979 hasConcept C104849204 @default.
• W3109106979 hasConcept C126322002 @default.
• W3109106979 hasConcept C126894567 @default.
• W3109106979 hasConcept C134018914 @default.
• W3109106979 hasConcept C159641895 @default.
• W3109106979 hasConcept C168563851 @default.
• W3109106979 hasConcept C170493617 @default.
• W3109106979 hasConcept C197934379 @default.
• W3109106979 hasConcept C2778653478 @default.
• W3109106979 hasConcept C2778930706 @default.
• W3109106979 hasConcept C2779561371 @default.
• W3109106979 hasConcept C2779716603 @default.
• W3109106979 hasConcept C2780091579 @default.
• W3109106979 hasConcept C2780306776 @default.
• W3109106979 hasConcept C2908929049 @default.
• W3109106979 hasConcept C71924100 @default.
• W3109106979 hasConcept C84393581 @default.
• W3109106979 hasConcept C90924648 @default.
• W3109106979 hasConceptScore W3109106979C104849204 @default.
• W3109106979 hasConceptScore W3109106979C126322002 @default.
• W3109106979 hasConceptScore W3109106979C126894567 @default.
• W3109106979 hasConceptScore W3109106979C134018914 @default.
• W3109106979 hasConceptScore W3109106979C159641895 @default.
• W3109106979 hasConceptScore W3109106979C168563851 @default.
• W3109106979 hasConceptScore W3109106979C170493617 @default.
• W3109106979 hasConceptScore W3109106979C197934379 @default.
• W3109106979 hasConceptScore W3109106979C2778653478 @default.
• W3109106979 hasConceptScore W3109106979C2778930706 @default.
• W3109106979 hasConceptScore W3109106979C2779561371 @default.
• W3109106979 hasConceptScore W3109106979C2779716603 @default.
• W3109106979 hasConceptScore W3109106979C2780091579 @default.
• W3109106979 hasConceptScore W3109106979C2780306776 @default.
• W3109106979 hasConceptScore W3109106979C2908929049 @default.

• next